Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors (ME-344-001)

MEI Pharma

Status and phase

Completed

Phase 1

Conditions

Solid Tumors

Treatments

Drug: ME-344

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01544322

ME-344-001

Details and patient eligibility

About

The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.

Enrollment

24 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of informed consent
Male or female ≥ 18 years of age
Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives.
ECOG Performance status 0-1 (Appendix A)
A minimum life expectancy of 12 weeks
Adequate bone marrow, hepatic and renal function as evidenced by:
- Absolute neutrophil count (ANC) > 1.5 x 109/L
- Platelet count > 100 x 109/L
- Hemoglobin > 9.0 g/dL
- Serum bilirubin < 1.5 x ULN
- AST/ALT (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
- Serum creatinine < 1.5 x ULN
Adequate cardiac function as evidenced by:
- CK-MB within normal levels at baseline
- Troponin T within normal levels at baseline
- The average QTc from triplicate screening ECGs (every 5 minutes over a total of 15 minutes) must be < 470 msec to be eligible for the study. (If a patient has an average QTc interval >470 msec at screening, the screening ECG may be repeated twice (at least 24 hours apart).
- LV Ejection Fraction > lower limit of institutional normal level
All potentially fertile patients will agree to use an effective form of contraception during the study and for 30 days following the last dose of ME-344 (an effective form of contraception is defined as an oral contraceptive or a double barrier method).
At least 4 weeks must have elapsed prior to Day 1 Cycle 1 since prior chemotherapy (6 weeks for nitrosourea or mitomycin C), investigational drug or biologic therapy and any toxicity associated with these treatments has recovered to ≤ NCI-CTCAE Grade 1.
At least 21 days must have elapsed prior to Day 1 Cycle 1, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for "limited palliative radiotherapy", defined as a course of therapy encompassing <25% total bone marrow volume and not exceeding 30 Gy.

Exclusion criteria

Patients who are pregnant or breastfeeding
Tumor involvement of the Central Nervous System (CNS):
- Patients with treated and stable CNS metastases may be eligible to participate after discussion and approval from the Medical Monitor
Uncontrolled infection or systemic disease.
Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.
Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Limited palliative radiation, defined as encompassing <25% of total bone marrow volume and not exceeding a total dose of 30 Gy, within the last 14 days.
Chemotherapy regimens with delayed toxicity within the last 4 weeks (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential or delayed toxicity within the last 2 weeks.
No concurrent systemic chemotherapy or biologic therapy is allowed.
Known hypersensitivity to any components of ME-344 study drug product.
Known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both).
History of solid organ transplantation.
Psychiatric disorder or social or geographic situation that would preclude study participation.